News
SpyBiotech Appoints Dr. Prakash Bhuyan as Chief Medical Officer
12 August, 2024
SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV)
23 July, 2024
SpyBiotech Appoints Keith Dewedoff as new Chief Financial Officer
18 June, 2024
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
23 May, 2024
7 December, 2023
SpyBiotech Announces MHRA Clinical Trial Application Filing for SPYVLP01
13 February, 2023
SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer
12 July, 2022
A study using SpyBiotech’s vaccine technology shows its potential against Covid-19 and other Coronaviruses
29 April, 2022
SpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific team
16 November, 2021
SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor
8 March, 2021
SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman
10 February, 2021
Study from Scripps using SpyTag/SpyCatcher for display of SARS-CoV-2 RBD on ferritin nanoparticles for vaccine development
8 October, 2020
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
Covid-19 vaccine candidates using SpyCatcher/SpyTag to display Spike protein on computationally designed particles and Bacteriophage VLPs
7 Sep 2020